Rapidemic

Executive Summary

Rapidemic is a Dutch biotechnology company founded in 2020 that aims to transform the diagnosis of sexually transmitted infections (STIs) through rapid, accurate, and decentralized point-of-care testing. Current STI diagnostics rely on lab-based PCR or antigen tests, leading to delayed results, reduced patient follow-up, and continued transmission. Rapidemic’s molecular platform enables clinic- and home-based testing with results in minutes, breaking down barriers related to privacy, convenience, and access. By targeting the global rise in STI incidence and leveraging the shift toward patient-centric care, the company addresses a critical unmet need in public health. Its initial focus is on chlamydia and gonorrhea, with potential expansion to other pathogens. The platform combines isothermal amplification with a disposable cartridge and reader, aiming to deliver lab-grade sensitivity without infrastructure requirements. As a private, early-stage venture, Rapidemic has not disclosed funding or valuation, but its innovation aligns with trends in decentralized diagnostics and digital health. The company's success hinges on regulatory clearance, manufacturing scale-up, and commercial partnerships to penetrate clinical and consumer markets. With growing awareness of STI prevention and the convenience of at-home testing, Rapidemic is well-positioned to capture a share of the expanding point-of-care diagnostics market.

Upcoming Catalysts (preview)

• Q4 2026CE-IVD certification of lead STI test70% success
• Q3 2026Strategic distribution partnership in Europe50% success
• Q2 2026Series A funding round completion60% success